Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
- Conditions
- Dengue
- Interventions
- Biological: rDEN3Δ30Biological: TetraVax-DV-TV005Biological: Placebo
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2018-03-08
- Target Recruit Count
- 48
- Registration Number
- NCT02873260
- Locations
- 🇺🇸
Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
🇺🇸University of Vermont Testing Center, Burlington, Vermont, United States
Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
- Conditions
- HIV Infections
- Interventions
- Biological: MVA/HIV62B vaccineBiological: AIDSVAX B/E vaccineBiological: Placebo
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2022-08-08
- Target Recruit Count
- 27
- Registration Number
- NCT02852005
- Locations
- 🇺🇸
Seattle Vaccine and Prevention CRS, Seattle, Washington, United States
🇺🇸Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
🇺🇸The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults
- Conditions
- Prevention of Zika InfectionZika-Specific Immune Response
- Interventions
- Biological: VRC-ZKADNA085-00-VP
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2019-03-18
- Target Recruit Count
- 80
- Registration Number
- NCT02840487
- Locations
- 🇺🇸
Hope Clinic - Emory Vaccine Ctr, Decatur, Georgia, United States
🇺🇸University of Maryland Ctr. for Vaccine Development, Baltimore, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
- Conditions
- HIV-1
- Interventions
- Biological: VRC-HIVMAB075-00-ABBiological: VRC-HIVMAB080-00-AB
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2021-02-23
- Target Recruit Count
- 16
- Registration Number
- NCT02840474
- Locations
- 🇺🇸
University of Alabama HIV Clinic Clinical Research Site, AIDS Clinical Trials Group (ACTG), Birmingham, Alabama, United States
🇺🇸University of Cincinnati University Hospital, AIDS Clinical Trials Group (ACTG), Cincinnati, Ohio, United States
🇺🇸Washington University Therapeutics, AIDS Clinical Trials Group (ACTG), Saint Louis, Missouri, United States
Using Biomarkers to Predict TB Treatment Duration
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Procedure: Saliva collectionProcedure: Urine collectionProcedure: Sputum collectionProcedure: Blood CollectionRadiation: PET/CT ScanDrug: Isoniazid, Rifampicin, Pyrazinamide and Ethambutol
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2024-04-17
- Target Recruit Count
- 946
- Registration Number
- NCT02821832
- Locations
- 🇿🇦
Clinical Infectious Diseases Research Initiative (Khayelitsha site), Cape Town, South Africa
GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
- Conditions
- Ebola
- Interventions
- Drug: GS-5734Other: Placebo Comparator
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2022-02-15
- Target Recruit Count
- 38
- Registration Number
- NCT02818582
- Locations
- 🇱🇷
JFK Hospital Partnership for Research for Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia
🇬🇳Partnership of Clinical Research in Guinea (PREGUI) / Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Forécariah, Maferinyah, Guinea
Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids
- Conditions
- Normal Physiology
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2023-06-22
- Target Recruit Count
- 33
- Registration Number
- NCT02798523
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults
- Conditions
- HIV Infections
- Interventions
- Biological: VRC01LSBiological: VRC01
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2024-03-20
- Target Recruit Count
- 80
- Registration Number
- NCT02797171
- Locations
- 🇺🇸
Case Clinical Research Site, Cleveland, Ohio, United States
🇺🇸Penn Prevention CRS, Philadelphia, Pennsylvania, United States
🇺🇸Seattle Vaccine and Prevention CRS, Seattle, Washington, United States
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: PlaceboBiological: RSV LID ΔM2-2 1030s vaccine
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2018-08-27
- Target Recruit Count
- 33
- Registration Number
- NCT02794870
- Locations
- 🇺🇸
Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States
🇺🇸Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States
🇺🇸Johns Hopkins University Center for Immunization Research, Baltimore, Maryland, United States
Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure
- Conditions
- Healthy Volunteers
- Interventions
- Biological: rVSV-Zebov GP vaccine
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2024-12-27
- Target Recruit Count
- 99
- Registration Number
- NCT02788227
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States